CKD-MBD — Mineral Bone Disease
CKD Stage
Mwongozo wa kina unakuja hivi karibuni
Tunafanya kazi kwenye mwongozo wa kielimu wa kina wa CKD-MBD Risk Assessment. Rudi hivi karibuni kwa maelezo ya hatua kwa hatua, fomula, mifano halisi, na vidokezo vya wataalamu.
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic syndrome that occurs as CKD progresses, characterised by disturbances in calcium (Ca), phosphate (PO4), parathyroid hormone (PTH), vitamin D, and fibroblast growth factor 23 (FGF-23). These biochemical derangements produce a spectrum of pathological consequences including bone disease (renal osteodystrophy), vascular and soft tissue calcification, and increased cardiovascular morbidity and mortality. As GFR falls below 60 mL/min/1.73m², phosphate retention triggers a compensatory rise in FGF-23 (from bone osteocytes), which suppresses renal 1-alpha-hydroxylase activity, reducing conversion of 25-OH vitamin D to its active form 1,25-dihydroxyvitamin D (calcitriol). Falling calcitriol reduces intestinal calcium absorption, lowering serum calcium and directly stimulating PTH secretion by the parathyroid glands. PTH elevation (secondary hyperparathyroidism) attempts to maintain calcium by mobilising bone mineral and increasing renal phosphate excretion, but as GFR declines, this compensatory mechanism becomes maladaptive — leading to high bone turnover, osteoporosis, and increased fracture risk. In dialysis patients, prolonged severe secondary hyperparathyroidism can become autonomous (tertiary hyperparathyroidism), requiring cinacalcet or parathyroidectomy. Vascular calcification driven by high calcium-phosphate product and uraemic toxins significantly increases cardiovascular risk, the leading cause of death in CKD. KDIGO 2017 CKD-MBD guidelines provide stage-specific targets for Ca, PO4, PTH, and vitamin D, with treatment encompassing dietary phosphate restriction, phosphate binders, vitamin D supplementation, calcimimetics, and parathyroidectomy for refractory cases.
Calcium-Phosphate Product = Serum Ca (mmol/L) × Serum PO4 (mmol/L); PTH target varies by CKD stage: G3a-G5 — keep within normal laboratory range; G5D (dialysis) — target 2-9 × upper limit of normal (KDIGO 2017)
- 1Measure serum calcium (corrected for albumin: corrected Ca = measured Ca + 0.02 × (40 - albumin g/L)), serum phosphate, PTH (intact or whole molecule assay), 25-OH vitamin D, and in selected cases 1,25-dihydroxyvitamin D and FGF-23
- 2Calculate the calcium-phosphate ion product (Ca × PO4 in mmol/L × mmol/L); a value above 4.4 mmol²/L² indicates increased risk of ectopic calcification — though this threshold is a historic guideline marker and not absolute
- 3Assess PTH relative to the laboratory upper limit of normal (ULN) and the patient's CKD stage: in CKD G3a-G5 the KDIGO target is to maintain PTH within the normal range (typically 1-65 pg/mL); in dialysis patients (G5D), target PTH 2-9× ULN, acknowledging that overly suppressed PTH risks adynamic bone disease
- 4Check 25-OH vitamin D level and correct deficiency (< 50 nmol/L) before prescribing active vitamin D analogues; active vitamin D (calcitriol, alfacalcidol) should be used when PTH is rising despite replete 25-OH vitamin D stores
- 5Assess bone disease type when clinically indicated — bone biopsy with tetracycline labelling is the gold standard to classify: high-turnover disease (osteitis fibrosa cystica from hyperparathyroidism), low-turnover disease (adynamic bone disease, often from oversuppressed PTH), or mixed disease
- 6Treat in a step-wise approach: dietary phosphate restriction first, then phosphate binders (calcium-based or non-calcium-based), active vitamin D for PTH control, cinacalcet (calcimimetic) in dialysis patients with elevated PTH, and parathyroidectomy for severe refractory tertiary hyperparathyroidism
- 7Monitor biochemistry at intervals determined by CKD stage — more frequently in advanced CKD (every 1-3 months in dialysis patients) and after treatment changes; use trends rather than single values for treatment decisions
Address vitamin D deficiency first, then consider active vitamin D and phosphate binders
25-OH vitamin D deficiency is driving reduced calcitriol and thus PTH rise. Correcting 25-OH vitamin D with cholecalciferol, adding a non-calcium phosphate binder (given PO4 > 1.5 mmol/L), and adding alfacalcidol or calcitriol are appropriate sequential steps.
Parathyroidectomy referral indicated — calcitriol is driving hypercalcaemia and should be withheld
Long-standing secondary hyperparathyroidism has become autonomous (PTH secretion no longer suppressed by calcium). Cinacalcet may be tried but surgical parathyroidectomy is likely needed. Active vitamin D must be withheld while hypercalcaemia persists.
Stop calcitriol; switch to non-calcium phosphate binder; target PTH 2-9× ULN
Adynamic bone disease is characterised by absent or minimal bone remodelling due to oversuppressed PTH. It predisposes to fractures, hypercalcaemia (calcium cannot be deposited in bone), and vascular calcification. The correction is to allow PTH to rise by removing calcium carbonate and calcitriol.
FGF-23 is the earliest biomarker of CKD-MBD — elevated before PO4 becomes abnormal
FGF-23 rises early in CKD to maintain serum phosphate by increasing renal phosphate excretion. By the time serum phosphate is elevated, FGF-23 is often markedly elevated. High FGF-23 independently predicts LVH, cardiovascular events, and CKD progression.
Guiding phosphate binder selection (calcium-based vs non-calcium-based) based on serum calcium, PTH level, and vascular calcification burden in CKD G3-G5D patients, where accurate renal osteodystrophy analysis through the Renal Osteodystrophy supports evidence-based decision-making and quantitative rigor in professional workflows
Monitoring response to active vitamin D analogues and cinacalcet in haemodialysis patients with secondary hyperparathyroidism, using quarterly PTH and monthly Ca/PO4 measurements, where accurate renal osteodystrophy analysis through the Renal Osteodystrophy supports evidence-based decision-making and quantitative rigor in professional workflows
Identifying candidates for parathyroidectomy referral when PTH is uncontrolled above 9× ULN despite optimised medical therapy, where accurate renal osteodystrophy analysis through the Renal Osteodystrophy supports evidence-based decision-making and quantitative rigor in professional workflows
Detecting early CKD-MBD in G3b-G4 patients by monitoring PTH and 25-OH vitamin D, initiating correction before severe hyperparathyroidism develops, where accurate renal osteodystrophy analysis through the Renal Osteodystrophy supports evidence-based decision-making and quantitative rigor in professional workflows
Evaluating and managing post-kidney transplant persistent hyperparathyroidism and hypercalcaemia, which affect bone health and graft function in the first 1-2 years after transplantation
Calciphylaxis (Calcific Uraemic Arteriolopathy)
Calciphylaxis is a medical emergency in dialysis patients characterised by painful skin necrosis from small vessel calcification. It is associated with severe CKD-MBD (high Ca × PO4, hyperparathyroidism), obesity, warfarin use, and hypoalbuminaemia. Management requires stopping all calcium-based binders and calcitriol, switching to non-calcium binders, intensive phosphate control, IV sodium thiosulphate (antioxidant and calcification inhibitor), urgent parathyroidectomy if PTH is extremely high, and expert wound care. Prognosis is poor without rapid intervention.
Adynamic Bone Disease
Adynamic bone disease is characterised by severely reduced bone remodelling and turnover, often from iatrogenic oversuppression of PTH (PTH < 2× ULN in dialysis patients). Bone biopsy shows reduced or absent osteoblast and osteoclast activity. It predisposes to fractures (bone cannot remodel microcracks), hypercalcaemia (calcium cannot be deposited), and vascular calcification. The key intervention is allowing PTH to rise by reducing or stopping calcitriol and switching from calcium-based to non-calcium phosphate binders.
Post-Kidney Transplant CKD-MBD
After successful kidney transplantation, hyperparathyroidism may persist for months to years despite recovery of renal function (tertiary or persistent secondary hyperparathyroidism), causing post-transplant hypercalcaemia and hypophosphataemia. GFR improvement restores 1-alpha-hydroxylase activity, raising calcitriol — combined with autonomous PTH — this causes significant hypercalcaemia. Cinacalcet is effective for post-transplant hypercalcaemia. Parathyroidectomy is reserved for severe refractory cases (typically PTH remains very high > 1 year post-transplant).
Bone Biopsy Indications
Bone biopsy with double tetracycline labelling (gold standard for diagnosing renal osteodystrophy) is indicated when: (1) unexplained fractures occur despite apparent adequate treatment; (2) PTH is in the indeterminate range (2-9× ULN) and the bone disease type is uncertain; (3) hypercalcaemia or hyperphosphataemia is refractory to standard therapy; or (4) before surgical treatment of hyperparathyroidism when adynamic bone disease must be excluded. Biopsy differentiates high-turnover (osteitis fibrosa), low-turnover (adynamic), osteomalacia, and mixed disease.
Vascular Calcification Monitoring
KDIGO recommends lateral abdominal X-ray (for aortic calcification) or echocardiography (for valvular calcification) to screen for vascular calcification in CKD G3-G5D patients. Presence of vascular calcification should be considered a cardiovascular risk equivalent and guide more aggressive CKD-MBD management. Coronary calcium scoring by CT can quantify coronary calcification burden but is not routinely recommended in all CKD patients. Vascular calcification in CKD is strongly associated with cardiovascular mortality.
| CKD Stage | Calcium Target | Phosphate Target | PTH Target | Vitamin D |
|---|---|---|---|---|
| G3a-G3b | Normal range (2.1-2.5 mmol/L) | Normal range (0.87-1.49 mmol/L) | Maintain normal (avoid elevation) | Correct deficiency (25-OH VD ≥ 50 nmol/L) |
| G4 | Normal range | Normal to high-normal (< 1.5 mmol/L) | Consider treatment if rising trend | Correct deficiency; active VD if PTH rising |
| G5 (pre-dialysis) | Normal range | Target normal range | Maintain within lab normal | Active vitamin D (calcitriol/alfacalcidol) |
| G5D (dialysis) | 2.1-2.5 mmol/L | Target normal range (0.87-1.49 mmol/L) | 2-9× upper limit of normal | Active vitamin D; adjust per Ca/PO4 |
| All stages | Avoid hypercalcaemia | Avoid hyperphosphataemia | Avoid extreme suppression | Avoid toxicity (hypercalcaemia, hyperphosphataemia) |
What is the difference between renal osteodystrophy and CKD-MBD?
Renal osteodystrophy is the term for the bone disease component specifically — the histological changes in bone structure due to CKD, including osteitis fibrosa cystica (from hyperparathyroidism), osteomalacia (from vitamin D deficiency), adynamic bone disease (from oversuppressed PTH), and mixed disease. CKD-MBD is the broader systemic term adopted by KDIGO in 2006 that encompasses not only bone disease but also the biochemical disturbances (Ca, PO4, PTH, vitamin D, FGF-23) and extra-skeletal manifestations (vascular calcification, cardiovascular disease). Renal osteodystrophy is now considered a subset of CKD-MBD.
What is the KDIGO PTH target for dialysis patients?
KDIGO 2017 CKD-MBD guidelines recommend targeting iPTH (intact PTH) at 2 to 9 times the upper limit of normal for the assay used in dialysis patients (CKD G5D). This wide range reflects the uncertainty about the optimal PTH target and the need to avoid both extremes: very high PTH (severe high-turnover disease, osteitis fibrosa) and very low PTH (adynamic bone disease). Regular monitoring with treatment adjustments guided by trends is recommended over a single numeric target.
What phosphate binders are available and when are they used?
Calcium-based binders (calcium carbonate, calcium acetate) are cheap and effective but can cause hypercalcaemia, suppress PTH excessively, and may promote vascular calcification. Non-calcium binders include sevelamer carbonate/hydrochloride (a polymer, also reduces LDL), lanthanum carbonate, ferric citrate (also treats iron deficiency), and sucroferric oxyhydroxide. KDIGO recommends preferring non-calcium binders in patients with hypercalcaemia, arterial calcification, adynamic bone disease, or persistently low PTH. All phosphate binders must be taken with meals to bind dietary phosphate.
What is cinacalcet and how does it work?
Cinacalcet (Sensipar) is a calcimimetic — it allosterically activates the calcium-sensing receptor (CaSR) on parathyroid cells, making them respond as if calcium is higher than it actually is. This suppresses PTH secretion, reducing PTH, phosphate, and calcium-phosphate product. It is licenced for secondary hyperparathyroidism in dialysis patients and for parathyroid carcinoma. It must not be used if corrected calcium is below 2.1 mmol/L (hypocalcaemia) as it lowers ionised calcium. Common side effects are nausea and vomiting.
What is the calcium-phosphate product and is it still clinically relevant?
The calcium-phosphate ion product (Ca × PO4) is a simple calculation that historically used a threshold of 4.4 mmol²/L² (or 55 mg²/dL² in conventional units) to identify risk of metastatic calcification. Modern KDIGO guidelines have moved away from relying on this threshold as a target, recognising that it oversimplifies a complex process and does not account for the role of inhibitors of calcification. However, the concept remains useful clinically — high Ca × PO4 is a marker of combined biochemical risk, and both Ca and PO4 should be maintained individually within target ranges.
When is parathyroidectomy indicated in CKD?
Parathyroidectomy is indicated for severe hyperparathyroidism (typically PTH > 800-1000 pg/mL) that is refractory to medical therapy (phosphate binders, active vitamin D, cinacalcet) and accompanied by symptoms or complications: hypercalcaemia, hyperphosphataemia, severe bone pain, pathological fractures, pruritus, or calciphylaxis. It is preferred over cinacalcet when the parathyroids are autonomous (tertiary hyperparathyroidism) or when the patient has calciphylaxis with hypercalcaemia. Total parathyroidectomy with autotransplantation or subtotal parathyroidectomy are the two surgical approaches.
What is calciphylaxis and how is it related to CKD-MBD?
Calciphylaxis (calcific uraemic arteriolopathy) is a rare but life-threatening complication characterised by calcification of small-medium skin arterioles causing painful ischaemic skin necrosis, typically on the abdomen, thighs, and buttocks. It occurs predominantly in dialysis patients and is associated with high Ca × PO4, elevated PTH, low protein C and S, obesity, warfarin use, and calcium-based phosphate binder use. Mortality from secondary infection is very high (> 50% at 1 year). Management includes strict phosphate and calcium control, non-calcium phosphate binders, sodium thiosulphate (intravenously), parathyroidectomy if PTH is severely elevated, wound care, and stopping warfarin.
What is FGF-23 and why is it important in CKD-MBD?
Fibroblast growth factor 23 (FGF-23) is a phosphaturic hormone produced by osteocytes in bone. It increases renal phosphate excretion (via the sodium-phosphate cotransporter NaPi-IIa) and reduces 1,25-dihydroxyvitamin D synthesis by inhibiting renal 1-alpha-hydroxylase. FGF-23 rises very early in CKD (from G2-G3a) before any rise in serum phosphate or PTH — it is the earliest measurable biomarker of CKD-MBD. Markedly elevated FGF-23 independently predicts left ventricular hypertrophy, cardiovascular mortality, and CKD progression. FGF-23 is not yet a routine clinical test in most centres but is increasingly measured in research and specialist settings.
Kidokezo cha Pro
Always correct serum calcium for albumin before interpreting CKD-MBD biochemistry. In clinical practice: corrected Ca (mmol/L) = measured Ca + 0.02 × (40 - serum albumin in g/L). Hypoalbuminaemia (common in CKD) causes measured calcium to appear deceptively low, leading to inappropriate treatment decisions.
Je, ulijua?
The parathyroid glands were the last major endocrine glands to be discovered — they were first described by Ivar Sandstrom, a Swedish medical student, in 1880. They are so small (4 glands, each roughly the size of a grain of rice, totalling 120-140 mg) that surgeons sometimes struggle to find them even during deliberate surgical exploration — a particular challenge in parathyroidectomy for renal hyperparathyroidism.
Marejeo
- ›KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD
- ›Moe S et al — KDIGO: Definition, Evaluation, and Classification of Renal Osteodystrophy (Kidney International 2006)
- ›Cunningham J et al — Osteoporosis in CKD (AJKD 2004)
- ›Gutierrez O et al — Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HD (NEJM 2008)
- ›EVOLVE Trial — Effect of Cinacalcet on Cardiovascular Disease in HD Patients (NEJM 2012)